Estefania Carlos
Research Subjects
Research Interests
Estefania Carlos has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Lydia Alvarez-Erviti
Laboratory of Molecular Neurobiology, Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain
2 shared publications - Maria Izco
Laboratory of Molecular Neurobiology, Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain
2 shared publications - César Domínguez
Departamento de Matemticas y Computacin, Universidad de La Rioja, Logroo, Spain
1 shared publication - Eloy Mata
Universidad de La Rioja
1 shared publication - Guglielmo Verona
National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus Rowland Hill Street, London NW3 2PF, UK
1 shared publication - Jónathan Heras
Department of Mathematics and Computer Science, University of La Rioja, Logroño, Spain
1 shared publication
Latest Publications
- 25 June 2023
- Published by Springer Nature
- p. 593-602
MicrogliaJ: An Automatic Tool for Microglial Cell Detection and Segmentation
- 25 June 2023
- Published by Springer Nature
- p. 593-602
MicrogliaJ: An Automatic Tool for Microglial Cell Detection and Segmentation
- Open Access
- 13 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1230
Targeted Extracellular Vesicle Gene Therapy for Modulating Alpha-Synuclein Expression in Gut and Spinal Cord
The development of effective disease-modifying therapies to halt Parkinson’s disease (PD) progression is required. In a subtype of PD patients, alpha-synuclein pathology may start in the enteric nervous system (ENS) or autonomic peripheral nervous system. Consequently, strategies to decrease the expression of alpha-synuclein in the ENS will be an approach to prevent PD progression at pre-clinical stages in these patients. In the present study, we aimed to assess if anti-alpha-synuclein shRNA-minicircles (MC) delivered by RVG-extracellular vesicles (RVG-EV) could downregulate alpha-synuclein expression in the intestine and spinal cord. RVG-EV containing shRNA-MC were injected intravenously in a PD mouse model, and alpha-synuclein downregulation was evaluated by qPCR and Western blot in the cord and distal intestine. Our results confirmed the downregulation of alpha-synuclein in the intestine and spinal cord of mice treated with the therapy. We demonstrated that the treatment with anti-alpha-synuclein shRNA-MC RVG-EV after the development of pathology is effective to downregulate alpha-synuclein expression in the brain as well as in the intestine and spinal cord. Moreover, we confirmed that a multidose treatment is necessary to maintain downregulation for long-term treatments. Our results support the potential use of anti-alpha-synuclein shRNA-MC RVG-EV as a therapy to delay or halt PD pathology progression.
- 13 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1230
Open AccessTargeted Extracellular Vesicle Gene Therapy for Modulating Alpha-Synuclein Expression in Gut and Spinal Cord
The development of effective disease-modifying therapies to halt Parkinson’s disease (PD) progression is required. In a subtype of PD patients, alpha-synuclein pathology may start in the enteric nervous system (ENS) or autonomic peripheral nervous system. Consequently, strategies to decrease the expression of alpha-synuclein in the ENS will be an approach to prevent PD progression at pre-clinical stages in these patients. In the present study, we aimed to assess if anti-alpha-synuclein shRNA-minicircles (MC) delivered by RVG-extracellular vesicles (RVG-EV) could downregulate alpha-synuclein expression in the intestine and spinal cord. RVG-EV containing shRNA-MC were injected intravenously in a PD mouse model, and alpha-synuclein downregulation was evaluated by qPCR and Western blot in the cord and distal intestine. Our results confirmed the downregulation of alpha-synuclein in the intestine and spinal cord of mice treated with the therapy. We demonstrated that the treatment with anti-alpha-synuclein shRNA-MC RVG-EV after the development of pathology is effective to downregulate alpha-synuclein expression in the brain as well as in the intestine and spinal cord. Moreover, we confirmed that a multidose treatment is necessary to maintain downregulation for long-term treatments. Our results support the potential use of anti-alpha-synuclein shRNA-MC RVG-EV as a therapy to delay or halt PD pathology progression.